Evidence map›Paper›PMID 40918464›Full record

Observational studyOncology research2025

First-Line Aumolertinib in

Xi Qin, Yulan Liu, Lin Zhu, Yunyan Mo, Jing Zhang, Zhuchun Jiang, Dongning Huang, Xinrong Hu, Jingzhang Li, Quanfang Chen and 1 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xi QinDepartment of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
Yulan LiuDepartment of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
Lin ZhuDepartment of Radiotherapy, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
Yunyan MoDepartment of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
Jing ZhangDepartment of Oncology, Guilin People's Hospital, Guilin, 541300, China.
Zhuchun JiangDepartment of Oncology and Integrated Traditional Chinese and Western Medicine, The People's Hospital of Hezhou, Hezhou, 542899, China.
Dongning HuangDepartment of Oncology, Liuzhou Workers' Hospital, Liuzhou, 545001, China.
Xinrong HuDepartment of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541002, China.
Jingzhang LiDepartment of Oncology, Liuzhou People's Hospital, Liuzhou, 545001, China.
Quanfang ChenDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
Feng XueDepartment of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases. Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint. Adverse events (AEs) were assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Results: Approximately 47 patients with Conclusion: This study concluded that aumolertinib has considerable safety and efficacy for

Indexed as

AcrylamidesCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationProtein Kinase InhibitorsAdultAgedAged, 80 and overAniline CompoundsErbB ReceptorsFemaleFollow-Up StudiesHumansIndolesMaleMiddle AgedAcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesAumolertinibepidermal growth factor receptor (EGFR)non-small cell lung cancer (NSCLC)real worldsafety

Identifiers

PMID40918464
PMCPMC12408845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.